Ginkgo Bioworks Holdings (DNA) Equity Average (2020 - 2026)

Ginkgo Bioworks Holdings has reported Equity Average for 7 years, with the latest figure at $475.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 30.2% year-over-year to $475.9 million; the trailing twelve-month figure through Mar 2026 stood at $475.9 million (down 30.2% YoY), and the FY2025 full-year result was $612.3 million, down 32.46% from the prior year.
• Equity Average for Q1 2026 stood at $475.9 million, down from $534.2 million in the prior quarter.
• The five-year high for Equity Average was $1.7 billion in Q1 2023, with the low at $475.9 million in Q1 2026.
• Historically, Equity Average has averaged $1.1 billion across 5 years, with a median of $1.0 billion in 2024.
• Annual changes were most pronounced in 2022 — Equity Average surged 324.77% — and 2024, when it plunged 41.49%.
• Ginkgo Bioworks Holdings' Equity Average stood at $1.6 billion in 2022, then retreated by 26.11% to $1.2 billion in 2023, then tumbled by 35.57% to $757.0 million in 2024, then declined by 29.43% to $534.2 million in 2025, then slipped by 10.92% to $475.9 million in 2026.
• The last three Equity Average figures came in at $475.9 million (Q1 2026), $534.2 million (Q4 2025), and $586.4 million (Q3 2025), per Business Quant data.